The U.S. Food and Drug Administration has approved Sanofi and Regeneron's Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (CSU). This ...

Sanofi (SNY) and Regeneron’s (REGN) Dupixent was approved in the U.S. as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria, the companies said on Wednesday ...

Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is better than Dupixent.

Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis (65%), asthma (20%), and CRSwNP (10%) as core indications; each faces varying competitive pressures. Revenue projections for ...

The FDA approval of the biologic drug Dupixent for allergic fungal rhinosinusitis may help patients living with this challenging condition and help them avoid repeat surgeries. The U.S. Food and Drug ...

What Is Dupixent, and Why Does It Matter? Dupixent (dupilumab) is a prescription medicine for treating various allergic conditions and is given as a shot under the skin. The FDA has now approved ...

However, as with any major medical treatment, the transition from clinical trials to the “real world” often leads to questions that aren’t always covered in a standard doctor’s visit. Patients are ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) yesterday announced that Japan's Ministry of Health, Labor and Welfare has approved Dupixent for children aged 6 to 11 years with ...

Regeneron Pharmaceuticals and Sanofi have won European Commission expanded approval of their blockbuster anti-inflammatory drug Dupixent for certain patients with the inflammatory skin condition ...

If you begin using Dupixent (dupilumab) and it works well for your condition, there’s no set time at which you would stop the medication. In most cases, you’ll stay on Dupixent long term, or as long ...

Sanofi and Regeneron Pharmaceuticals said their jointly developed Dupixent anti-inflammatory blockbuster drug achieved primary and secondary goals in a late-stage study for allergic fungal ...